Dr. Levine joined MSK in 2007 after completing fellowship training in hematology and oncology at Dana-Farber Cancer Institute and was jointly appointed as an Assistant Member in the Human Oncology and Pathogenesis Program (HOPP) and on the Leukemia Service in the Department of Medicine.
In 2019, he became the first Service Chief of the Molecular Cancer Medicine Service in HOPP, after serving as inaugural Director of the Center for Hematologic Malignancies since 2016.
In 2022, Dr. Levine was appointed Deputy Physician-in-Chief of Translational Research at Memorial Hospital (MH), and then Senior Vice President for MH Translational Research in 2024. In that capacity, he was responsible for developing a coordinated effort to support translational research across the hospital and overseeing the activities of the MH Collaborative Research Centers, HOPP, and all MH laboratory-based research.
Dr. Levine also serves as the Edward P. Evans Endowed Chair for Myelodysplastic Syndromes at MSK. He is an internationally recognized leader and physician-scientist dedicated to researching and treating blood and bone marrow cancers. His research lab focuses on understanding the genetic basis for the development of myeloid malignancies and using this insight to seek better therapies.
Dr. Levine is the recipient of many awards and honors, including MSK’s Excellence in Mentoring Award, the Dameshek Prize from the American Society of Hematology, the Pershing Square Sohn Prize for Cancer Research, the Laurence Joseph Dineen Chair in Leukemia Research, a Scholar Award from the Leukemia and Lymphoma Society, the Boyer Award for Clinical Investigation from MSK, and an NCI Outstanding Investigator R35 Award.
Dr. Levine earned his medical degree from the Johns Hopkins University School of Medicine and completed a residency in internal medicine at Massachusetts General Hospital.
